Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin
Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin
复制标题
DOI：
10.1016/j.vaccine.2005.04.037
复制
发表时间：
2005-09-15
期刊：
影响因子：
5.5
通讯作者：
Vitetta, ES
中科院分区：
文献类型：
--
作者：
Smallshaw, JE;Richardson, JA;Vitetta, ES
Ricin toxin is a plant-derived ribosome inactivating protein (RIP) of extraordinary toxicity. Vaccination using ricin toxoid or its A chain (RTA) is protective in animals but both vaccines have two potential toxicities, RIP and vascular leak syndrome (VLS). Previously we described three recombinant RTA constructs from which both toxicities were eliminated by site-specific mutations. One mutant, V76M/Y80A, RiVax, has now been further characterized for immunogenicity and toxicity in animals. We have found that RiVax is safe at doses of at least 8 mg in mice, 800-fold higher than the protective dose, and induces neutralizing antibodies in both mice and rabbits. (c) 2005 Elsevier Ltd. All rights reserved.
